论文部分内容阅读
目的:探讨非小细胞肺癌(NSCLC)中p53、CD44V6及nm23/NDPK表达的相关性及预后意义。方法:采用免疫组织化学SP法对69例NSCLC组织中p53、CD44V6及nm23/NDPK进行检测。结果:p53、CD44V6及nm23/NDPK的表达与NSCLC患者的临床分期(P<0.05,P<0.01)、淋巴结转移(P<0.05,P<0.01)及生存率(P<0.05)密切相关。p53、CD44V6表达与nm23/NDPK在NSCLC中的表达呈明显负相关(P<0.01)。结论:联合检测NSCLC中p53、CD44V6及nm23/NDPK的表达对于判断预后和指导治疗可能具有实用价值。
Objective: To investigate the correlation and prognostic significance of p53, CD44V6 and nm23 / NDPK expression in non-small cell lung cancer (NSCLC). Methods: Immunohistochemical SP method was used to detect p53, CD44V6 and nm23 / NDPK in 69 NSCLC tissues. Results: The expressions of p53, CD44V6 and nm23 / NDPK were closely related to the clinical stage (P <0.05, P <0.01), lymph node metastasis (P <0.05, P <0.01) and survival rate (P <0.05) in NSCLC patients. The expression of p53 and CD44V6 was negatively correlated with the expression of nm23 / NDPK in NSCLC (P <0.01). Conclusion: The combined detection of p53, CD44V6 and nm23 / NDPK expression in NSCLC may be of practical value in judging the prognosis and guiding treatment.